Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (40) 40
male (40) 40
female (35) 35
middle aged (27) 27
aged (25) 25
adult (22) 22
chemotherapy (19) 19
care and treatment (18) 18
lung cancer (16) 16
oncology (16) 16
lung neoplasms - drug therapy (13) 13
cancer (12) 12
analysis (11) 11
hematology, oncology and palliative medicine (11) 11
lung cancer, non-small cell (11) 11
lung neoplasms - pathology (11) 11
neoplasm staging (11) 11
prognosis (11) 11
treatment outcome (11) 11
carcinoma, non-small-cell lung - drug therapy (10) 10
mutation (10) 10
aged, 80 and over (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
japan (9) 9
medical research (9) 9
animals (8) 8
cancer therapies (8) 8
metastasis (8) 8
survival (8) 8
clinical trials (7) 7
research (7) 7
respiratory system (7) 7
trial (7) 7
tumors (7) 7
clinical neurology (6) 6
lung neoplasms - mortality (6) 6
medical colleges (6) 6
medicine, experimental (6) 6
metaanalysis (6) 6
patients (6) 6
abridged index medicus (5) 5
carcinoma, non-small-cell lung - genetics (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
diagnosis (5) 5
expression (5) 5
follow-up studies (5) 5
health aspects (5) 5
lung cancer, small cell (5) 5
lung neoplasms - genetics (5) 5
magnetic resonance imaging (5) 5
rats (5) 5
safety (5) 5
tyrosine (5) 5
usage (5) 5
carcinoma (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
cardiac & cardiovascular systems (4) 4
college teachers (4) 4
combination (4) 4
confidence intervals (4) 4
docetaxel (4) 4
gefitinib (4) 4
iii trial (4) 4
immunotherapy (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
motivation (4) 4
multicenter (4) 4
neurosciences (4) 4
nsclc (4) 4
protein-tyrosine kinase (4) 4
pulmonary/respiratory (4) 4
radiotherapy (4) 4
rats, sprague-dawley (4) 4
risk factors (4) 4
small cell lung carcinoma - pathology (4) 4
solid tumors (4) 4
survival analysis (4) 4
therapy (4) 4
antineoplastic agents - therapeutic use (3) 3
apoptosis (3) 3
biomarkers (3) 3
child (3) 3
cisplatin - administration & dosage (3) 3
cohort studies (3) 3
disease control (3) 3
disease-free survival (3) 3
dna mutational analysis (3) 3
drug administration schedule (3) 3
epidermal growth factor receptors (3) 3
erlotinib (3) 3
etoposide (3) 3
gene expression (3) 3
gene rearrangement (3) 3
genes (3) 3
genetic aspects (3) 3
genetic disorders (3) 3
immunohistochemistry (3) 3
infant, newborn (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
by Seto, Takashi, MD and Kiura, Katsuyuki, Prof and Nishio, Makoto, MD and Nakagawa, Kazuhiko, Prof and Maemondo, Makoto, MD and Inoue, Akira, MD and Hida, Toyoaki, MD and Yamamoto, Nobuyuki, MD and Yoshioka, Hiroshige, MD and Harada, Masao, MD and Ohe, Yuichiro, MD and Nogami, Naoyuki, MD and Takeuchi, Kengo, MD and Shimada, Tadashi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
by Seto, Takashi, MD and Kato, Terufumi, MD and Nishio, Makoto, MD and Goto, Koichi, MD and Atagi, Shinji, MD and Hosomi, Yukio, MD and Yamamoto, Noboru, MD and Hida, Toyoaki, MD and Maemondo, Makoto, MD and Nakagawa, Kazuhiko, Prof and Nagase, Seisuke, MD and Okamoto, Isamu, MD and Yamanaka, Takeharu, PhD and Tajima, Kosei, MSc and Harada, Ryosuke, BS and Fukuoka, Masahiro, MD and Yamamoto, Nobuyuki, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
by Hida, Toyoaki, MD and Nokihara, Hiroshi, MD and Kondo, Masashi, MD and Kim, Young Hak, MD and Azuma, Koichi, MD and Seto, Takashi, MD and Takiguchi, Yuichi, Prof and Nishio, Makoto, MD and Yoshioka, Hiroshige, MD and Imamura, Fumio, MD and Hotta, Katsuyuki, Prof and Watanabe, Satoshi, MD and Goto, Koichi, MD and Satouchi, Miyako, MD and Kozuki, Toshiyuki, MD and Shukuya, Takehito, MD and Nakagawa, Kazuhiko, Prof and Mitsudomi, Tetsuya, Prof and Yamamoto, Nobuyuki, Prof and Asakawa, Takashi, PhD and Asabe, Ryoichi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
by Goss, Glenwood, Dr Prof and Tsai, Chun-Ming, Prof and Shepherd, Frances A, Prof and Bazhenova, Lyudmila, Prof and Lee, Jong Seok, MD and Chang, Gee-Chen, MD and Crino, Lucio, MD and Satouchi, Miyako, MD and Chu, Quincy, MD and Hida, Toyoaki, MD and Han, Ji-Youn, Prof and Juan, Oscar, MD and Dunphy, Frank, Prof and Nishio, Makoto, MD and Kang, Jin-Hyoung, MD and Majem, Margarita, MD and Mann, Helen, MSc and Cantarini, Mireille, MD and Ghiorghiu, Serban, MD and Mitsudomi, Tetsuya, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1643 - 1652
Summary Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | GEFITINIB | TKI | NSCLC | ONCOLOGY | ACQUIRED-RESISTANCE | T790M MUTATION | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | ErbB Receptors - antagonists & inhibitors | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Piperazines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Lung cancer, Non-small cell | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
by Shaw, Alice T, Dr and Kim, Tae Min, MD and Crinò, Lucio, Prof and Gridelli, Cesare, MD and Kiura, Katsuyuki, MD and Liu, Geoffrey, MD and Novello, Silvia, Prof and Bearz, Alessandra, MD and Gautschi, Oliver, MD and Mok, Tony, Prof and Nishio, Makoto, MD and Scagliotti, Giorgio, Prof and Spigel, David R, MD and Deudon, Stéphanie, PharmD and Zheng, Cheng, PhD and Pantano, Serafino, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Viraswami-Appanna, Kalyanee, PhD and Felip, Enriqueta, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Summary Background Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has shown robust anti-tumour efficacy, along with... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | RESISTANCE | TRANSLOCATION | GENE | ONCOLOGY | SAFETY | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Pyrazoles - therapeutic use | gamma-Glutamyltransferase - blood | Humans | Middle Aged | Sulfones - adverse effects | Lung Neoplasms - pathology | Male | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Adult | Female | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Docetaxel | Disease Progression | Disease-Free Survival | Retreatment | Aspartate Aminotransferases - blood | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Pyrimidines - therapeutic use | Gene Rearrangement | Pyrimidines - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Lymphomas | Research institutes | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
by Takahashi, Toshiaki, MD and Yamanaka, Takeharu, Prof and Seto, Takashi, MD and Harada, Hideyuki, MD and Nokihara, Hiroshi, MD and Saka, Hideo, MD and Nishio, Makoto, MD and Kaneda, Hiroyasu, MD and Takayama, Koichi, MD and Ishimoto, Osamu, MD and Takeda, Koji, MD and Yoshioka, Hiroshige, MD and Tachihara, Motoko, MD and Sakai, Hiroshi, MD and Goto, Koichi, MD and Yamamoto, Nobuyuki, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Summary Background Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases... 
Hematology, Oncology and Palliative Medicine | DIAGNOSIS | METAANALYSIS | THERAPY | COMPLETE REMISSION | CISPLATIN | ONCOLOGY | RISK | ASYMPTOMATIC BRAIN METASTASES | Lung Neoplasms - drug therapy | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Early Termination of Clinical Trials | Brain Neoplasms - secondary | Aged, 80 and over | Medical Futility | Adult | Female | Survival Rate | Cranial Irradiation - adverse effects | Brain Neoplasms - prevention & control | Small Cell Lung Carcinoma - prevention & control | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Small Cell Lung Carcinoma - diagnostic imaging | Watchful Waiting | Aged | Platinum Compounds - administration & dosage | Care and treatment | Chemotherapy | Lung cancer | Oncology, Experimental | Radiation | Clinical trials | Metastasis | Research | College teachers | Radiotherapy | Cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
by Goto, Koichi, Dr and Ohe, Yuichiro, MD and Shibata, Taro, MSc and Seto, Takashi, MD and Takahashi, Toshiaki, MD and Nakagawa, Kazuhiko, Prof and Tanaka, Hiroshi, MD and Takeda, Koji, MD and Nishio, Makoto, MD and Mori, Kiyoshi, MD and Satouchi, Miyako, MD and Hida, Toyoaki, MD and Yoshimura, Naruo, MD and Kozuki, Toshiyuki, MD and Imamura, Fumio, MD and Kiura, Katsuyuki, Prof and Okamoto, Hiroaki, MD and Sawa, Toshiyuki, MD and Tamura, Tomohide, MD and JCOG0605 Investigators and JCOG0605 investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Summary Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY-GROUP | ETOPOSIDE/CISPLATIN | THERAPY | PROGNOSTIC-FACTORS | ONCOLOGY | CLINICAL-TRIALS | DISEASE | INTENSIVE WEEKLY CHEMOTHERAPY | COMBINATION | III TRIAL | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
by Yoh, Kiyotaka, Dr and Seto, Takashi, MD and Satouchi, Miyako, MD and Nishio, Makoto, MD and Yamamoto, Noboru, MD and Murakami, Haruyasu, MD and Nogami, Naoyuki, MD and Matsumoto, Shingo, MD and Kohno, Takashi, PhD and Tsuta, Koji, Prof and Tsuchihara, Katsuya, MD and Ishii, Genichiro, MD and Nomura, Shogo, MSc and Sato, Akihiro, MD and Ohtsu, Atsushi, MD and Ohe, Yuichiro, MD and Goto, Koichi, MD
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Summary Background RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase... 
Pulmonary/Respiratory | ALK | CABOZANTINIB | RESPIRATORY SYSTEM | MEDULLARY-THYROID CANCER | ADENOCARCINOMA | FUSION GENE | MUTATIONS | IDENTIFICATION | TUMORIGENESIS | III TRIAL | CHEMOTHERAPY | CRITICAL CARE MEDICINE | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Piperidines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Gene Order | Proto-Oncogene Proteins c-ret - genetics | Treatment outcome | Care and treatment | Vandetanib | Safety and security measures | Analysis | Dosage and administration | Lung cancer, Non-small cell | Clinical trials | Usage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
by Jänne, Pasi A, Dr Prof and Ou, Sai-Hong I, MD and Kim, Dong-Wan, MD and Oxnard, Geoffrey R, MD and Martins, Renato, Prof and Kris, Mark G, Prof and Dunphy, Frank, Prof and Nishio, Makoto, MD and O'Connell, Joseph, MD and Paweletz, Cloud, PhD and Taylor, Ian, PhD and Zhang, Hui, PhD and Goldberg, Zelanna, MD and Mok, Tony, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1433 - 1441
Summary Background Patients with EGFR -mutant non-small-cell lung cancer generally have a progression-free survival of 9–13 months while being treated with the... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | THERAPY | ONCOLOGY | ADENOCARCINOMA | RESISTANCE | EGFR MUTATIONS | QUALITY-OF-LIFE | AFATINIB | INHIBITOR | ERLOTINIB | CHEMOTHERAPY | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Survival Rate | Molecular Targeted Therapy | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Adult | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolinones - therapeutic use | Neoplasm Staging | Clinical trials | Medical colleges | Care and treatment | Lung cancer, Non-small cell | Tyrosine | Product development
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
by Kubota, Kaoru, Prof and Hida, Toyoaki, MD and Ishikura, Satoshi, MD and Mizusawa, Junki, MSc and Nishio, Makoto, MD and Kawahara, Masaaki, MD and Yokoyama, Akira, MD and Imamura, Fumio, MD and Takeda, Koji, MD and Negoro, Shunichi, MD and Harada, Masao, MD and Okamoto, Hiroaki, MD and Yamamoto, Nobuyuki, MD and Shinkai, Tetsu, MD and Sakai, Hiroshi, MD and Matsui, Kaoru, MD and Nakagawa, Kazuhiko, Prof and Shibata, Taro, MSc and Saijo, Nagahiro, Prof and Tamura, Tomohide, MD and Japan Clinical Oncology Grp and Japan Clinical Oncology Group
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Summary Background Four cycles of etoposide plus cisplatin and accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard of care for... 
Hematology, Oncology and Palliative Medicine | UNITED-STATES | IRRADIATION | METAANALYSIS | ETOPOSIDE/CISPLATIN | ONCOLOGY | EARLY PALLIATIVE CARE | CLINICAL-TRIALS | JAPAN | DISEASE | COMBINATION | III TRIAL | Lung Neoplasms - mortality | Humans | Middle Aged | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Carcinoma, Small Cell - mortality | Chemoradiotherapy | Cisplatin - administration & dosage | Carcinoma, Small Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Camptothecin - administration & dosage | Dose Fractionation | Female | Aged | Carcinoma, Small Cell - pathology | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Nuclear radiation | Lung cancer | Etoposide | College teachers | Radiotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
by Kiyotaka, YOH, MD and HOSOMI, Yukio, MD, PhD and KASAHARA, Kazuo, MD, PhD and YAMADA, Kazuhiko, MD, PhD and TAKAHASHI, Toshiaki, MD and YAMAMOTO, Nobuyuki, MD, PhD and NISHIO, Makoto, MD, PhD and Yuichiro, OHE, MD, PhD and Toshiko, KOUE, PhD and NAKAMURA, Takashi, MPH and ENATSU, Sotaro, MD, PhD and Pablo, LEE, MD and FERRY, David, PhD and TAMURA, Tomohide, MD and NAKAGAWA, Kazuhiko, MD, PhD
Lung Cancer, ISSN 0169-5002, 2016, Volume 99, pp. 186 - 193
Highlights • We assessed second-line ramucirumab-docetaxel in Japanese patients with NSCLC. • Ramucirumab-docetaxel PFS was longer than placebo-docetaxel PFS... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non-small-cell lung cancer | Randomized phase II trial | Ramucirumab | Japan | Docetaxel | TRIAL | MULTICENTER | GEFITINIB | ONCOLOGY | RESPIRATORY SYSTEM | COMBINATION | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Platinum - administration & dosage | Taxoids - therapeutic use | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Risk Factors | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - pharmacokinetics | Retreatment | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Antimitotic agents | Medical research | Communicable diseases | Medicine, Experimental | Respiratory agents | Cross infection | Nosocomial infections | Lung cancer, Non-small cell | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy
by Hamanaka, Wakako, MD, PhD and Motoi, Noriko, MD, PhD and Ishikawa, Shumpei, MD, PhD and Ushijima, Masaru, PhD and Inamura, Kentaro, MD, PhD and Hatano, Satoko and Uehara, Hirofumi, MD, PhD and Okumura, Sakae, MD and Nakagawa, Ken, MD and Nishio, Makoto, MD, PhD and Horai, Takeshi, MD, PhD and Aburatani, Hiroyuki, MD, PhD and Matsuura, Masaaki, PhD and Iwasaki, Akinori, MD, PhD and Ishikawa, Yuichi, MD, PhD
Human Pathology, ISSN 0046-8177, 2014, Volume 45, Issue 5, pp. 1045 - 1056
Summary Patients with small cell lung carcinoma (SCLC) rarely demonstrate long-term survival. We previously reported that gene expression profiling identified... 
Pathology | Immunohistochemistry | Prognosis | Neuroendocrine | Basal cell | Small cell lung cancer (SCLC) | METAANALYSIS | STATE | PATHOLOGY | TRIAL | SPECIMENS | ADHESION MOLECULE | CISPLATIN | RADIOTHERAPY | SERUM MARKERS | CARCINOMA | Biomarkers, Tumor - analysis | Lung Neoplasms - mortality | CD56 Antigen - analysis | Humans | Middle Aged | Male | Small Cell Lung Carcinoma - surgery | Gene Expression Profiling | Membrane Proteins - analysis | Keratins - analysis | Small Cell Lung Carcinoma - pathology | Biopsy | Carcinoma, Neuroendocrine - pathology | Protein Array Analysis | Female | Aged | Chromogranin A - analysis | Synaptophysin - analysis | Small Cell Lung Carcinoma - chemistry | Research | Gene expression | Oncology, Experimental | Analysis | Cancer | Genetic research | Medical research | Chemotherapy | Medical prognosis | Classification | Histology | Tumors | Smoking
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights